Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gust

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Archiv Der Pharmazie|May 31, 2001
1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic propertiesS Schertl, R W Hartmann, C Batzl-Hartmann, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1990
[DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancerR Müller, R Gust, G Bernhardt, et al.
Investigative Radiology|August 18, 2000
Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbitsS A Schmitz, S E Coupland, R Gust, et al.
Archiv Der Pharmazie|September 1, 1995
Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activityR Gust, G Bernhardt, T Spruss, et al.
Lancet (London, England)|May 30, 2001
Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trialB W Böttiger, C Bode, S Kern, et al.
Archiv Der Pharmazie|March 1, 1990
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part II: Biological evaluation-in vitro studies on the P 388 D1 leukemia cell lineH Reile, R Müller, R Gust, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1990
Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexesH D vom Orde, H Reile, R Müller, et al.
Archiv Der Pharmazie|January 1, 1989
Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: SynthesisM Jennerwein, R Gust, R Müller, et al.
Archiv Der Pharmazie|February 1, 1989
Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological propertiesM Jennerwein, R Gust, R Müller, et al.
Journal of Medicinal Chemistry|January 1, 1988
Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinomaJ Karl, R Gust, T Spruss, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Archiv Der Pharmazie|May 31, 2001
1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic propertiesS Schertl, R W Hartmann, C Batzl-Hartmann, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1990
[DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancerR Müller, R Gust, G Bernhardt, et al.
Investigative Radiology|August 18, 2000
Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbitsS A Schmitz, S E Coupland, R Gust, et al.
Archiv Der Pharmazie|September 1, 1995
Development of a parenterally administrable hydrosol preparation of the "third generation platinum complex" [(+/-)-1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activityR Gust, G Bernhardt, T Spruss, et al.
Lancet (London, England)|May 30, 2001
Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trialB W Böttiger, C Bode, S Kern, et al.
Archiv Der Pharmazie|March 1, 1990
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part II: Biological evaluation-in vitro studies on the P 388 D1 leukemia cell lineH Reile, R Müller, R Gust, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1990
Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexesH D vom Orde, H Reile, R Müller, et al.
Archiv Der Pharmazie|January 1, 1989
Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: SynthesisM Jennerwein, R Gust, R Müller, et al.
Archiv Der Pharmazie|February 1, 1989
Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological propertiesM Jennerwein, R Gust, R Müller, et al.
Journal of Medicinal Chemistry|January 1, 1988
Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinomaJ Karl, R Gust, T Spruss, et al.
Pageof 8